MarginsXMarginsX
Home › Markets › Health Care › ANNX

Annexon Inc. (ANNX)

ANNX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.57
-8.93% on the day
Market cap
$681.0M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerANNX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001528115
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
6.5 months
$102.4M cash at September 30, 2026
Share count, 1 year
+59.5%
2025-10-31 to 2026-11-05
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
$12.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$102.4M cash; operating cash flow -$47.4M a quarter.Report 2026-09-30
Shares outstanding190,763,984 (2026-11-05); 119,632,804 a year earlier.Cover page 2026-11-05
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-03-31
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Francisco, California, United StatesPCAOB Form AP 2026-04-21
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $12.4M, sold $286K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$51.2M-$48.7M$102.4M$49.3MNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$55.3M-$48.0M$199.3MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2026
2026-03-31
Not filed-$44.1M-$46.8M$175.2MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2025
2025-12-31
Not filed-$48.3M-$45.9M$162.1M$0Needs four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$54.9M-$52.3M$139.4MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$49.2M-$38.1M$132.3MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q1 2025
2025-03-31
Not filed-$54.4M-$50.1M$97.1MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q4 2024
2024-12-31
Not filed-$48.6M-$36.0M$49.5MNo debt tagsNeeds four quarters10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-03-31
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 525 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.7%
1 month+2.3%
3 months-25.5%
Year to date-21.9%
1 year+46.3%
From 52-week high-43.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
APMDApnimed Inc.$16.28-3.78%$677.7M
JANXJanux Therapeutics Inc.$10.92-3.96%$668.1M
ALMSAlumis Inc.$5.14-8.21%$667.3M
NVCTNuvectis Pharma Inc.$19.11-5.58%$657.2M
KURAKura Oncology Inc.$7.09-8.75%$651.4M
BCAXBicara Therapeutics Inc.$9.75-2.69%$647.3M
ANLAdlai Nortye Group Ltd.$10.03-5.47%$645.9M
OLMAOlema Oncology Inc.$7.36-2.65%$644.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier